Wildy Michael, Lu Ping
Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.
Materials (Basel). 2023 Nov 7;16(22):7062. doi: 10.3390/ma16227062.
Electrospun nanofibers for drug delivery systems (DDS) introduce a revolutionary means of administering pharmaceuticals, holding promise for both improved drug efficacy and reduced side effects. These biopolymer nanofiber membranes, distinguished by their high surface area-to-volume ratio, biocompatibility, and biodegradability, are ideally suited for pharmaceutical and biomedical applications. One of their standout attributes is the capability to offer the controlled release of the active pharmaceutical ingredient (API), allowing custom-tailored release profiles to address specific diseases and administration routes. Moreover, stimuli-responsive electrospun DDS can adapt to conditions at the drug target, enhancing the precision and selectivity of drug delivery. Such localized API delivery paves the way for superior therapeutic efficiency while diminishing the risk of side effects and systemic toxicity. Electrospun nanofibers can foster better patient compliance and enhanced clinical outcomes by amplifying the therapeutic efficiency of routinely prescribed medications. This review delves into the design principles and techniques central to achieving controlled API release using electrospun membranes. The advanced drug release mechanisms of electrospun DDS highlighted in this review illustrate their versatility and potential to improve the efficacy of medical treatments.
用于药物递送系统(DDS)的电纺纳米纤维引入了一种革命性的药物给药方式,有望提高药物疗效并减少副作用。这些生物聚合物纳米纤维膜以其高比表面积、生物相容性和生物可降解性为特点,非常适合药物和生物医学应用。它们的突出特性之一是能够实现活性药物成分(API)的控释,允许定制释放曲线以满足特定疾病和给药途径的需求。此外,刺激响应性电纺DDS可以适应药物靶点处的条件,提高药物递送的精准性和选择性。这种局部API递送为提高治疗效果铺平了道路,同时降低了副作用和全身毒性的风险。电纺纳米纤维可以通过提高常规处方药的治疗效果来促进更好的患者依从性并改善临床结果。本综述深入探讨了使用电纺膜实现API控释的核心设计原则和技术。本综述中强调的电纺DDS的先进药物释放机制展示了它们的多功能性以及改善医疗治疗效果的潜力。